MAVACAMTEN 
| MAVACAMTEN | CARDIOVASCULAR CARDIAC MYOSIN INHIBITOR TREATMENT OF NEW YORK HEART ASSOCIATION (NYHA) II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) | ORAL | Tmax 1 HOUR F 85 PERCENT PPB 98 PERCENT HT 180 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER AT PH 2-10 | CARDIAC MYOSIN | More at DrugCentral | ANSM (in French) Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |